Sessions

Implementing and Integrating Disruptive Technologies for Commercial Benefit
Workshop: Investment in CGT – Securing Funding for your Biotech Venture
People Behind the Cures: Recruitment, Opportunity and Diversity for the CGT Workforce
Commercializing Gene Therapies: Building Your Strategy From Translation Through to Commercial
Cell Therapy Commercial Success, Overcoming Pitfalls and What We Have Learned from 2022
Paying for Cures: Creative Payment, Reimbursement, Market Access Models and Defining Value in the CGT Space
Patient-Centric Development: Keeping the Patient at the Heart of Commercializing New Medicines

test

Implementing and Integrating Disruptive Technologies for Commercial Benefit

20 Jan 2023
09:00
Commercializing the Therapies of the Future Track
SPONSORED BY
ARMI
Landmark Bio

9:00am Chair Introduction

Tom Bollenbach, Chief Technology Officer, Advanced Regenerative Manufacturing Institute (ARMI)

 

9:05am Presentation: TBC

Ryan Crisman, Co-Founder and Chief Technical Officer, Umoja Biopharma

 

9:20am Presentation: TBC

Zhimei Du, Vice President, Translational Research and Early Development, Landmark Bio

 

9:35am Presentation: TBC

Sven Kili, Chief Executive Officer, Antion Biosciences

 

9:50am Presentation: TBC

Speaker TBC

 

10:05am Closing Panel with Q&A

With all session participants

Speakers

Ryan Crisman
Chief Technical Officer
Umoja Biopharma
Sven Kili
Chief Executive Officer
Antion Biosciences
Thomas Bollenbach
Chief Technology Officer
ARMI
Zhimei Du
Vice President, Translational Research and Early Development
Landmark Bio